Supernus, Inc. (SUPN)
NASDAQ: SUPN Β· Real-Time Price Β· USD
29.27
+0.23 (0.77%)
Nov 18, 2026, 1:00 PM EST - Market open
β View all transcripts
Jefferies Global Healthcare Conference
Nov 16, 2026
Summary
The completed Indivior merger creates a ~$2.2B-revenue business with leverage below 1x and a focus on growing key CNS products, advancing pipeline assets and pursuing deals. SUBLOCADE, ONAPGO and Qelbree updates outlined growth drivers and 2027 considerations.
Okay. We're going to get started. I'm Andrew Tsai, Senior Biotech Analyst at Jefferies. Thank you for joining us day one of our London conference. It's my pleasure to have Jack Khattar, CEO of Supernus. Welcome, Jack.
Thank you. Thanks for having me.
Big changes going on this year for you, Jack. There are some people who may be revisiting the story, so could you kind of give us the latest and greatest about Supernus and your priorities over the next year?
Yeah, sure. Thank you for being here. Just quick reminder, I'll be making forward-looking statements, so please check our SEC filings for all the risk factors associated with the business. This is actually a very exciting time for us at Supernus. We just completed the merger with Indivior Pharmaceuticals. On a pro forma basis that we had communicated when we announced the merger, you're looking at a company of about $2.2 billion in revenue and a fairly healthy adjusted EBITDA of north of $800 million. So it's a very substantial business. We're focused on CNS. The primary therapeutic areas are addiction, opioid use disorder, specifically SUBLOCADE, which is the leading product in that space. Then Qelbree, which is for ADHD as a leading novel non-stimulant in that space. ZURZUVAE, which is the only product approved actually for postpartum depression.
It's been a great product in partnership with Biogen. Also we have a healthy Parkinson's franchise, primarily with ONAPGO, which is the only apomorphine infusion device that we launched about a year and a half ago, together with GOCOVRI, which is the only Parkinson's product approved for off episodes and dyskinesia. So we have a really nice collection of products that are growth products that should get us well into the 2030 and beyond that. In addition to that, we have a nice pipeline also of couple products in Phase 2b, one which is a unique epilepsy product, SPN-817, and then SPN-820, which is a first-in-class depression program that we have also going on. Very healthy balance sheet.
After the merger close, we have leverage which is less than 1x, so we have a tremendous financial flexibility and capacity to continue to do some of the things we've done historically by bringing products from the outside as well funding our own R&D activities.
Mm. Congratulations on the progress. With the merger of equals done with Indivior, are you the one who drives all the decisions? When we think about guidance, you issuing new guidance, spending on this program, is it your decision or how does this all work?
Well, I mean, we're one team right now, so we are Supernus. It doesn't matter where you came from as an employee, we're all Supernus employees as one team, one company. The leadership team came mainly from Supernus. We had a couple members who came from Indivior side, but at the end of the day, we're now the new Supernus, so to speak, and we all manage the company as one team and one company.
Understood. When you report Q4 earnings, is that the time we can expect you to issue new 2027 guidance with the SUBLOCADE and Indivior products, or is it JP Morgan?
Yeah, I mean, typically we don't pre-announce our historic practice, so to speak. We don't pre-announce around the JP Morgan. I think we'll follow the same path in a way. We'll issue the guidance in February around the earnings, yeah, for 2027.
This year, with your 2026 guidance, you're helpful in breaking out certain individual product guidance. Is that something you would entertain in 2027, ONAPGO, Indivior products, for instance?
We are looking at it now. I mean, realizing, of course, we're a much bigger company. We have some really key important products. Now, historically, we did it only in few occasions when necessary. For example, of course, ONAPGO, because of the supply situation, we had to give people at least a bracket, the situation for them for 2026. Same thing, we did that on Trokendi XR, Oxtellar XR when they went generic, so that we can isolate the growth products from the legacy products. So remains to be seen. We are looking at it, see if we can be as helpful as possible, but typically I'm against having to get into the minutia of every single product, especially when you have 11 products now in the portfolio.
Right. Okay. I personally get EBITDA 2027 year end, or 27 of like $1.1 billion. To grow that EBITDA conceptually, for 2027, are you spending more to drive more top line growth, or is this kind of, in terms of the expense structure, this is pretty good on the SG&A front?
Yeah, I mean, our priorities moving forward is, the first thing is our existing growth products. We did mention several times that we're going to continue to invest behind clearly SUBLOCADE, Qelbree, ONAPGO, ZURZUVAE, and to a much lesser degree, GOCOVRI, of course. So that's really our primary top priority, make sure these products are maxed out as far as the growth potential behind them, and we have a long runway on pretty much all of them. The second priority is, of course, continue to advance our pipeline and the development of our products that are currently in the phase II stage. Then we will continue, and we are always active on the BD front, in bringing other products and other opportunities for the company.
Now, at the same time, of course, we realize we are a bigger company, much bigger scale, a lot of cash generation, so we will continue to look at also a balanced approach, maybe from a capital allocation perspective. I know a lot of folks have asked me about share buyback and so forth. I mean, all these are under consideration and will be considered to do the best for our shareholders. But I do remind people also, we are in the pharma business. Pharma business, you always need more products, you always need more products that come in either internally or from the outside. So we got to balance all that, obviously, as time goes on.
Okay, very clear. In terms of BD, you mentioned you're less than one times your leverage. How high can you go, and how much firepower do you think you'll have come, say, year end of 2027?
Yeah, I mean, it really depends on the opportunity you're looking at at that time, clearly about its power of generating cash flows and how much leverage it might sustain or not sustain. Obviously, that's always on a case-by-case scenario. But in general, philosophically, we don't like to over-leverage. That's not who we are. We try to run it in a more conservative way. So we're comfortable with a 2.5, maybe 3x as far as leverage eventually. But again, for the right opportunity and depending on the cash flows and the longevity and the quality of these cash flows, could you go a little bit higher? Yes, but that's not something we're too comfortable with.
Yes
typically.
And in terms of the opportunity, remind us the latest thinking, which indications, what stage? Sounds like you like late stage to commercial at the moment.
Yeah, I mean, from a strategic perspective, our criteria haven't changed much. We continue to favor, of course, commercial assets. If not commercial, something late stage, because if you look at our pipeline right now, the two lead programs are in phase IIb. So if we were to acquire something, we would like it to be much more advanced, to give us a potential product launch maybe in the 2029 to 2030, 2031 window, so to speak. That would be great. As far as therapeutic areas, clearly our four top therapeutic areas, I mean, will be addiction, ADHD, so we're going to be in psychiatry, neurology, movement disorders. I mean, these are the rare diseases, these are the things that we're focused on.
Thanks. Okay. Maybe shifting gears to then SUBLOCADE. Revenues, I think, were They're over a billion run rate right now. It's growing. So fundamentally, can you just walk us through why this is differentiated over the other OUD products out there, like Brixadi, for instance?
Yeah, I mean, the real exciting thing about SUBLOCADE, and that's why we really got excited about the potential here, and that's why we did the transaction that we did, is it's a very well-differentiated product in general. The clinical profile, the PK profile is truly differentiated. What I mean by that is on several fronts. First, if you look at the doses, we can go as high as 300 milligram. Why is that important? In this specific disease, occupancy of the opioid receptors is extremely important, and the amount of time and the sustained levels of delivery is extremely important for sustained recovery and long-term recovery. If you don't have sustained plasma concentrations, you have the risk of relapse, you have the risk of overdose, you have the risk of withdrawal, you have all kind of issues that patients unfortunately go through.
But if you have a very consistent delivery, with very strong PK profile that delivers plasma concentrations at the top end. What I mean by top end is, our doses, the high doses, can get us to two to three nanograms per mil as far as plasma concentration. These are the plasma concentrations that have been shown to actually result in 70%-80% receptor occupancy. That is so important to get to these levels and get it in a consistent manner. Consistent manner, and that's where also our product is different from the other products. Its half-life is 43 to 60 days. It's very important when you have monthly injections, because a lot of these patients typically are not as good routinely to have these appointments, get their injections on time.
Sometimes they're three days late, five days late, or even a week and a half late in getting their next appointment, next injection. So if you don't have a long half-life, all of a sudden your blood levels are going to drop, and you're going to be at a risk of obviously, cravings, withdrawals, and then could lead to overdose or could lead to the use of oral drugs. You already disrupted the recovery cycle, and now you got to start again. That's really horrible for our patients because we're trying to give them every chance possible here with the best hope for a long-lasting recovery. SUBLOCADE does that. You hear that from physicians. I mean, this is not just a PK phenomena. It's real in medical and the clinical practice out there.
Physicians tell you, "When I have a patient on SUBLOCADE, I'm really not too worried if they don't show up, excuse me, on time, because I know they're covered. They have enough in their blood so they don't have to have a crisis and all of a sudden, they're in the hospital at some point." With other products, they worry about the relapse. They worry about the issues that could lead to ER visits or hospitalization. So, that makes a big difference for the physician and the comfort level in prescribing SUBLOCADE, but also more importantly, important to the patient. I mean, that's really because you want that patient not to have any chance of relapse, because every little setback could set back the whole process.
These patients go through a lot in making that decision to want to have that recovery, and they go sometimes through a lot of different ups and downs to finally get the chance. Once they are on SUBLOCADE, we want them to have the best chance possible for that long-lasting recovery. Because in real life, a lot of people do not realize it is attainable. You can actually get that long-lasting recovery. You just have to stick to it and have products that actually work for you and help you as much as possible.
Thanks. Makes a lot of sense. A $1.1 billion run rate right now. Can you remind us what kind of market penetration that is like and what the peak sales for this product could be?
Yeah, the key driving force here is the long-acting products as a segment in the market. The penetration of that, the size of that segment is still pretty small compared to the overall market. So, when you look at the LAI, long-acting formulations or products out there, they are only around 8%-10% of the market. When you look at the disease and some of the things I just talked about, sustainability of plasma concentration, long-lasting, these long-acting products are extremely important for patient recovery. Therefore, we continue to believe that this segment will continue to grow. Actually, you look at the past several years, it has grown in the 18%-23%. Year to date this year, 21% growth, so consistent growth.
The reason you are seeing this growth is there is more and more evidence and data that is coming out showing that long-acting products actually lead to recovery, lead to reduction in hospitalizations, in healthcare utilization, lowering of medical costs, and so forth. As more and more people use them and they get that positive reinforcement and feedback, clearly we continue to see that growth. Now, in addition to that, SUBLOCADE, as far as SUBLOCADE is concerned, we embarked on a DTC campaign in the fourth quarter of 2025, so it has been out for a while.
We already see significant metrics and improvement on awareness of the product, appreciation for what the product could potentially do, a lot of search activity on the website, but also location, trying to locate a physician next to you. We can see tremendous uptick in the traffic on all these software and searches. It is activating patients, not just increasing awareness, but it is leading them to take action and look for a physician and a clinic next to them to really seek help. That is very encouraging. Most likely we will continue that. We are in the middle of making these decisions as we speak on 2027 and the budget and the programs and so forth. As you might imagine, we just closed on the merger, so we are just putting all that together right now.
Understood. I think there was some pricing tailwind on gross-to-net earlier this year for SUBLOCADE. Is that the case, and is there a headwind going into 2026? How should we think about net price?
Well, as far as the gross-to-net, from understanding your question, I mean, historically the company has made some one-time adjustments on the gross-to-net because of Medicaid favorability on that side versus the estimates they used to have. That is going to go away over time. That does not sustain itself forever, these kind of one-time adjustments. So there had been a benefit basically in 2026 regarding because of these adjustments. We do not expect them to continue into 2027, because eventually your accruals and the actual data will end up matching up. You do not have that gap anymore.
I see. On the patent side, what is the IP life of SUBLOCADE?
Yeah, I mean, the product has about 12 or actually 13 patents in the Orange Book, so we have a significant patent estate around the product itself, and that goes till 2038 at the outer date. We also have a bunch of other applications that could go 2040 and beyond. So we have a significant patent estate around the product. It's been on the market now for six years or so we feel good about the position, and we felt comfortable, obviously, when we did the diligence and all that.
Mm. Indivior had some R&D projects, including an LAI project. What's your appetite to pursue those R&D projects?
We're looking at it right now. Clean page, so to speak, look at the projects and see why, were they discontinued, and is there a merit for us to bring them back or not? So that's under assessment as we speak.
Okay. Thanks. Moving on to ONAPGO, Parkinson's pump that launched in April of 2025. I think you've guided this year for that product to be, is it $60 million or $65 million for the year? Okay. How do you feel about the trajectory? Are you satisfied after fixing the supply issue earlier in the year? Remind us your latest view on the peak sales potential of this product.
Yeah. We're really happy, I mean, where we are with ONAPGO right now. All the supply issues are behind us. It's been quite a year, so to speak. If you were to step away from all the issues we had, last year we did $17 million in sales, and this year we're going to do $60 million-$65 million. Pretty good, actually, despite all the noise and the issues that we went through. We're in a great place right now. All the supply issues are behind us. We have a clear slate, so to speak, as far as the queue and the number of patients who are in the queue where we are processing their forms. We don't have the backlog that was created by the supply. All that has been cleared up. We're very focused now on We basically relaunched the product. That's what really happened.
We're back on track as far as building the demand, focusing on the patients. It will be interesting to see what the eventual peak potential, I know folks ask me all the time about that. It all boils down to who is that patient who is getting ONAPGO? What's the patient profile? Is it more on the advanced, severe, more progressed side, or are we getting patients who are more on the moderate side, less severe? The jury is still out at this point because of, it's still fairly new. Actually, you could do so many surveys. You might hit a physician at a time they're experimenting still with it and trying to figure out themselves within their practice what type of patient they're going to use ONAPGO on.
The early data point we got at one point, which we talked about in one of the earnings call, was that, and we were surprised with that, we're getting more younger patients, more active, younger, career-oriented type of patient, which surprised us a little bit because we always thought we probably will get older patients who had tried levodopa-carbidopa for so long that they're not getting any more incremental benefit from levodopa-carbidopa, and therefore they need something else like apomorphine. Maybe that's not the best assumption out there. Our peak sales that we have communicated to the street, $200 million-$300 million, probably is proving to be conservative right now. I'm not ready to change that until I get more data as to who is that patient. Not only who is that patient, how are they using it? Are they using one cartridge a day?
Are they using half a cartridge a day? These are all important things to really get our arms around before we put out another estimate from a peak sales perspective.
Understood. Supply doesn't seem to be an issue. It is a demand question. Investors always want more, Jack. What does it take to accelerate sales from here? Because ultimately, Parkinson's is a very big market.
It's doing what we do best, which is a grind every single day, fight for every patient, because we know a lot of patients will benefit from ONAPGO. The history speaks well for itself. It's been on the market in Europe for 20-plus years.
The product does remarkably well, and we have thousands and thousands of patients on the pump in Europe. That was after so many years, clearly. We know from a medical and clinical perspective, there is a huge demand for a product like this. It's very unique because of apomorphine as a different entity. Biologically, it acts exactly like dopamine, the affinity to receptors, all that, versus levodopa-carbidopa that has to actually be converted in the brain and metabolized by the neurons to become like a dopamine activity. What happens on Parkinson's patients over time? Well, you have less and less of these neurons to convert levodopa-carbidopa, and maybe that's why levodopa-carbidopa doesn't help you forever, right? You need something else more like apomorphine. We're very encouraged about the potential. It's just that we got to
Yes
keep fighting it out there and get every patient we can.
Very good. Moving on to Qelbree, I think it's almost a $400 million run rate drug after five years of launch. You have IP, is it out to 2035 now? So 2027, what's the key priority to driving more growth? Are you planning to do a DTC? I'm assuming it is grinding, so maybe talk to the 2027.
Yeah, adult segment continues to be very important for us, and we've been putting a lot of push behind adults in the last couple years, because it is the biggest segment and it's also the fastest-growing segment. Qelbree has really found a real nice place for itself within the adult population for numerous reasons. It works, it works fast. Although adults love their stimulants, so it's a little bit tougher of a battle to win patients over on a non-stimulant. But I think there is a lot of data around Qelbree as far as its utility in the adult patient population. The growth speaks for itself. So last quarter, we grew about 25% in prescriptions in the adult patient population. The quarter before, also 25% versus a year ago. So we continue to really put up very strong numbers.
At the same time, of course, growing on the pediatric side. This last back-to-school season, we had 19% growth, and this is, we're already in year six on Qelbree. So, and all in all, it's only 1% market share. All this, obviously, because it's a huge market, it's 111 million prescriptions a year, and we're right flirting with the million, a little bit north of million on an annual basis as far as prescriptions. So, we feel great about Qelbree, its potential. We have a lot of room ahead of us for the product. Clearly, we're always evaluating, are there different programs, different things we could do to accelerate growth? So that's always obviously the case.
Okay. Qelbree, the gross-to-net for 20 Can you remind us what that was for 2026 and how it should change in 2027?
Yeah, for 2026, for the first nine months altogether combined is about 53.5%. So it is right within our target, which we always talked about 50%-55%. As time goes on, we all know the story in this industry, gross-to-net never gets better. Unfortunately, over time, it always gets worse. So we expect 2027 probably be closer to the 55% rather the 50%, right? Because of the natural always increase in rebates, Medicaid also, there is a good portion of the business in Medicaid on Qelbree.
That is always obviously makes gross-to-net worse over time.
Okay, great. Moving on to ZURZUVAE, you are partnering with Biogen, 50/50 split. You recognize $160 million, I believe, this past. Actually, never mind. I just forget the sales that you put up.
Was it 41?
41. So it's about, yeah, 160 annualized. I actually wanted to ask about the pipeline that Sage had. I felt like there are a lot of interesting R&D assets in that. Is that something you would consider looking through and introducing to the public in the near future, like
Yeah,
next year?
we've been through the portfolio. We fairly scrubbed through it quite a bit now. It's been about a year since we acquired the business. We have prioritized the portfolio, rationalized it, and we've picked some programs we want to keep in our discovery engine, because we have a good number of people working on a lot of novel things. Right now, we have actually several platforms in discovery within Supernus, creating novel mechanisms and all that. And the ones that we don't want to carry forward because of priorities and resources whatsoever, we are and have been exploring potential out-licensing these molecules to other folks.
I see. Last question. You have the epilepsy and depression assets, like you said earlier, data timing for those phase II readouts?
Right now, it looks on the epilepsy, as you all know, these studies tend to be slower than others, probably in the 2028 timeframe. I do not know if we will have anything in 2027. We will see. The depression program also probably more early 2028. I do not know if there is a chance we could squeeze it in the 2027, remain to be seen.
Okay. Thanks for all the updates. Congratulations.
Thank you.
on all the execution. Thanks, everyone. Thanks, Jack.